POAI Predictive Oncology Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * MYERS ROBERT L	2. Issuer Name and Ticker or Trading Symbol Predictive Oncology Inc. [ POAI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Financial Officer
(Last)          (First)          (Middle) 2915 COMMERS DRIVE, SUITE 900	3. Date of Earliest Transaction (MM/DD/YYYY) 9/23/2021
(Street) EAGAN, MN 55121 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 par value	9/23/2021		M(2)		33334	A	$1.13 (1)	33411	D
Common Stock, $.01 par value	9/23/2021		D(3)		10200	D	$1.13	23211	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	9/23/2021		M			33334	(2)	(1)(2)	Common Stock	33334	$0	66666	D

Explanation of Responses:
(1)	Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock. The shares are delivered to the Reporting Person upon vesting.
(2)	On September 23, 2020, the reporting person was granted 100,000 restricted stock units, vesting in three annual installments beginning on the first anniversary of the grant date. The first of these installments vests on September 23, 2021. The remainder vests on each of 9/23/2022 and 9/23/2023.
(3)	10,200 shares of common stock forfeited to Company on September 23, 2021 to cover withholding tax, in accordance with Restricted Stock Unit Agreement between Reporting Person and Company.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
MYERS ROBERT L 2915 COMMERS DRIVE, SUITE 900 EAGAN, MN 55121			Chief Financial Officer

Signatures
/s/ Bob Myers		9/24/2021
**Signature of Reporting Person		Date